View in EDS

Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

Saved in:
Bibliographic Details
Title: Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.
Authors: Porter R; Dana-Farber Cancer Institute, Boston, Massachusetts, USA rebecca_porter@dfci.harvard.edu., Bockorny B; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Corr BR; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA., Mahadevan D; The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA., Wilky BA; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA., El-Khoueiry AB; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA., Bullock AJ; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Hafez N; The Angeles Clinic and Research Institute, Los Angeles, California, USA., Moser J; HonorHealth Research Institute, Scottsdale, Arizona, USA., Martynova A; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA., Stebbing J; Anglia Ruskin University, School of Life Sciences, Cambridge, England, UK., Joshi B; Agenus Inc, Lexington, Massachusetts, USA., Bourdelais S; Agenus Inc, Lexington, Massachusetts, USA., Delepine C; Agenus Inc, Lexington, Massachusetts, USA., Chand D; Agenus Inc, Lexington, Massachusetts, USA., Wu W; Agenus Inc, Lexington, Massachusetts, USA., Johnson B; Agenus Inc, Lexington, Massachusetts, USA., Grossman JE; Agenus Inc, Lexington, Massachusetts, USA., O'Day SJ; Agenus Inc, Lexington, Massachusetts, USA., Matulonis UA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Gordon MS; HonorHealth Research Institute, Scottsdale, Arizona, USA.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Dec 23; Vol. 13 (12). Date of Electronic Publication: 2025 Dec 23.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41436232
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Porter+R%22">Porter R</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, USA rebecca_porter@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Bockorny+B%22">Bockorny B</searchLink>; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Corr+BR%22">Corr BR</searchLink>; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Mahadevan+D%22">Mahadevan D</searchLink>; The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Wilky+BA%22">Wilky BA</searchLink>; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22El-Khoueiry+AB%22">El-Khoueiry AB</searchLink>; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Bullock+AJ%22">Bullock AJ</searchLink>; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hafez+N%22">Hafez N</searchLink>; The Angeles Clinic and Research Institute, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Moser+J%22">Moser J</searchLink>; HonorHealth Research Institute, Scottsdale, Arizona, USA.<br /><searchLink fieldCode="AU" term="%22Martynova+A%22">Martynova A</searchLink>; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Stebbing+J%22">Stebbing J</searchLink>; Anglia Ruskin University, School of Life Sciences, Cambridge, England, UK.<br /><searchLink fieldCode="AU" term="%22Joshi+B%22">Joshi B</searchLink>; Agenus Inc, Lexington, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Bourdelais+S%22">Bourdelais S</searchLink>; Agenus Inc, Lexington, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Delepine+C%22">Delepine C</searchLink>; Agenus Inc, Lexington, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Chand+D%22">Chand D</searchLink>; Agenus Inc, Lexington, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Wu+W%22">Wu W</searchLink>; Agenus Inc, Lexington, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Johnson+B%22">Johnson B</searchLink>; Agenus Inc, Lexington, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Grossman+JE%22">Grossman JE</searchLink>; Agenus Inc, Lexington, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22O'Day+SJ%22">O'Day SJ</searchLink>; Agenus Inc, Lexington, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Matulonis+UA%22">Matulonis UA</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Gordon+MS%22">Gordon MS</searchLink>; HonorHealth Research Institute, Scottsdale, Arizona, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2025 Dec 23; Vol. 13 (12). <i>Date of Electronic Publication: </i>2025 Dec 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41436232
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/jitc-2025-013222
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Porter R
      – PersonEntity:
          Name:
            NameFull: Bockorny B
      – PersonEntity:
          Name:
            NameFull: Corr BR
      – PersonEntity:
          Name:
            NameFull: Mahadevan D
      – PersonEntity:
          Name:
            NameFull: Wilky BA
      – PersonEntity:
          Name:
            NameFull: El-Khoueiry AB
      – PersonEntity:
          Name:
            NameFull: Bullock AJ
      – PersonEntity:
          Name:
            NameFull: Hafez N
      – PersonEntity:
          Name:
            NameFull: Moser J
      – PersonEntity:
          Name:
            NameFull: Martynova A
      – PersonEntity:
          Name:
            NameFull: Stebbing J
      – PersonEntity:
          Name:
            NameFull: Joshi B
      – PersonEntity:
          Name:
            NameFull: Bourdelais S
      – PersonEntity:
          Name:
            NameFull: Delepine C
      – PersonEntity:
          Name:
            NameFull: Chand D
      – PersonEntity:
          Name:
            NameFull: Wu W
      – PersonEntity:
          Name:
            NameFull: Johnson B
      – PersonEntity:
          Name:
            NameFull: Grossman JE
      – PersonEntity:
          Name:
            NameFull: O'Day SJ
      – PersonEntity:
          Name:
            NameFull: Matulonis UA
      – PersonEntity:
          Name:
            NameFull: Gordon MS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 12
              Text: 2025 Dec 23
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1